Engineering the Future of Pain Relief
We have harnessed the complexity of nature and genomics to develop the world’s first plant-based non-addictive pain medication.
Changing the Landscape of Opioid Pain Management
Effective Pain Relief without Addiction
Emerzene Inc is a biotechnology company on a mission to solve one of the biggest challenges with pain killers – synthetic addiction. We are the first company to use advanced gene editing techniques, enhanced CRISPR technology and sustainable agronomic practices for non-addictive poppy breeding.
OUR SCIENCE
IN COLLABORATION WITH:
A New Revolution in Pain Relief
As a vertically integrated biotechnology company, Emerzene applies research experience in agriculture and genomics to poppy cultivation.
Employing precision extraction of active pharmaceutical ingredients (API) as a production core, and conducting clinical studies to develop new treatments, we are the first company to use advanced genetics and CRISPR enhanced processes to develop a non-addictive strain of poppy.
INNOVATION
Plant Based. Organic. Sustainable.
We leverage synergies of plant genetics and biotechnology with sustainable agricultural production to make the critical advances necessary for medicine, human health and the environment.
Years of agronomy research, field experience and patented sustainable farming practices improve the resilience and long-term health of the soil--ultimately leading to higher yields and crop quality.
A Never-Ending Promise to Innovation
Our development began with a vision to tackle one of the biggest struggles of pain medications – chemical addiction. Thanks to our commitment to innovation, we developed exclusive methods to extract and purify our own perennial poppies.
With complete control of our own supply chain, we utilize a novel, water-based extraction process that does not require toxic solvents. Our highly efficient approach costs less than traditional extraction, not only producing a completely plant-based product but also giving us a wide competitive margin in API production costs.
Science
Emerzene is the first company to use advanced genetics and CRISPR technology for poppy breeding.
Manufacturing
To ensure premium quality extraction, we control and direct our own processes at our partnering facilities in Europe.
Our Values
We are passionate about the sustainable cultivation, innovative extraction processes, and management of a new species of poppy that will transform opioid pain management.
We are actively looking to partner with pharmaceutical companies for our R&D trials to propel the next generation of medicinal advances.
PARTNER WITH US
